Teva Pharmaceutical Industries Limited (TEVA) financial statements (2021 and earlier)
Company profile
| Business Address |
5 BAZEL ST PETACH TIKVA, 49131 |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2019 | 12/31/2018 | 12/31/2017 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments | 1,975 | 1,782 | 963 | ||
| Cash and cash equivalents | 1,975 | 1,782 | 963 | ||
| Receivables | 5,676 | 5,822 | 7,927 | ||
| Inventory, net of allowances, customer advances and progress billings | 4,422 | 4,731 | 4,924 | ||
| Inventory | 4,422 | 4,731 | 4,924 | ||
| Prepaid expense | 870 | 899 | |||
| Disposal group, including discontinued operation | 87 | 92 | |||
| Other current assets | 434 | 468 | |||
| Other undisclosed current assets | 1,568 | ||||
| Total current assets: | 13,464 | 13,794 | 15,382 | ||
| Noncurrent Assets | |||||
| Finance lease, right-of-use asset | 37 | ✕ | ✕ | ||
| Operating lease, right-of-use asset | 514 | ✕ | ✕ | ||
| Property, plant and equipment | 6,436 | 6,868 | 7,673 | ||
| Intangible assets, net (including goodwill) | 36,078 | 38,922 | 46,054 | ||
| Goodwill | 24,846 | 24,917 | 28,414 | ||
| Intangible assets, net (excluding goodwill) | 11,232 | 14,005 | 17,640 | ||
| Other noncurrent assets | 591 | 731 | 932 | ||
| Deferred tax assets, net | ✕ | (2,703) | |||
| Other undisclosed noncurrent assets | 350 | 368 | 3,277 | ||
| Total noncurrent assets: | 44,006 | 46,889 | 55,233 | ||
| TOTAL ASSETS: | 57,470 | 60,683 | 70,615 | ||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities, including: | 1,718 | 1,853 | 2,069 | ||
| Employee-related liabilities | 693 | 870 | |||
| Other undisclosed accounts payable and accrued liabilities | 1,025 | 983 | 2,069 | ||
| Debt | 2,345 | 2,216 | 3,646 | ||
| Other liabilities | 889 | 804 | 724 | ||
| Other undisclosed current liabilities | 8,722 | 9,449 | 11,482 | ||
| Total current liabilities: | 13,674 | 14,322 | 17,921 | ||
| Noncurrent Liabilities | |||||
| Long-term debt and lease obligation | 24,997 | 26,700 | 28,829 | ||
| Long-term debt, excluding current maturities | 24,562 | 26,700 | 28,829 | ||
| Operating lease, liability | 435 | ✕ | ✕ | ||
| Liabilities, other than long-term debt | 2,640 | 3,867 | 5,120 | ||
| Deferred tax liabilities, net | ✕ | 2,140 | 3,277 | ||
| Other liabilities | 2,640 | 1,727 | 1,843 | ||
| Other undisclosed noncurrent liabilities | 1,096 | ||||
| Total noncurrent liabilities: | 28,733 | 30,567 | 33,949 | ||
| Total liabilities: | 42,407 | 44,889 | 51,870 | ||
| Stockholders' equity | |||||
| Stockholders' equity attributable to parent | 13,972 | 14,707 | 17,359 | ||
| Preferred stock | 3,631 | ||||
| Common stock | 56 | 56 | 54 | ||
| Treasury stock, value | (4,128) | (4,142) | (4,149) | ||
| Additional paid in capital | 27,312 | 27,210 | 23,479 | ||
| Accumulated other comprehensive loss | (2,312) | (2,459) | (1,853) | ||
| Accumulated deficit | (6,956) | (5,958) | (3,803) | ||
| Stockholders' equity attributable to noncontrolling interest | 1,091 | 1,087 | 1,386 | ||
| Total stockholders' equity: | 15,063 | 15,794 | 18,745 | ||
| TOTAL LIABILITIES AND EQUITY: | 57,470 | 60,683 | 70,615 | ||
Income statement (P&L) ($ in millions)
| 12/31/2019 | 12/31/2018 | 12/31/2017 | ||
|---|---|---|---|---|
| Revenues | 16,887 | 18,854 | 23,584 | |
| Revenue, net | ✕ | ✕ | 22,385 | |
| Cost of revenue (Cost of Goods and Services Sold) | (9,351) | (10,558) | (11,560) | |
| Other undisclosed gross profit | 1 | (1,199) | ||
| Gross profit: | 7,537 | 8,296 | 10,825 | |
| Operating expenses | (4,816) | (4,147) | (4,986) | |
| Other operating income, net | 76 | |||
| Other undisclosed operating loss | (3,240) | (5,786) | (23,323) | |
| Operating loss: | (443) | (1,637) | (17,484) | |
| Nonoperating expense | (822) | (959) | (895) | |
| Interest and debt expense | (881) | (920) | (875) | |
| Other undisclosed income from continuing operations before equity method investments, income taxes | 881 | 920 | 875 | |
| Loss from continuing operations before equity method investments, income taxes: | (1,265) | (2,596) | (18,379) | |
| Loss from equity method investments | (13) | (71) | (3) | |
| Loss from continuing operations before income taxes: | (1,278) | (2,667) | (18,382) | |
| Income tax benefit | 278 | 195 | 1,933 | |
| Net loss: | (1,000) | (2,472) | (16,449) | |
| Net income attributable to noncontrolling interest | 2 | 322 | 184 | |
| Other undisclosed net loss attributable to parent | (1) | |||
| Net loss attributable to parent: | (999) | (2,150) | (16,265) | |
| Preferred stock dividends and other adjustments | (249) | (260) | ||
| Net loss available to common stockholders, diluted: | (999) | (2,399) | (16,525) | |
Comprehensive Income ($ in millions)
| 12/31/2019 | 12/31/2018 | 12/31/2017 | ||
|---|---|---|---|---|
| Net loss: | (1,000) | (2,472) | (16,449) | |
| Other comprehensive income (loss) | 160 | (585) | 1,306 | |
| Other undisclosed comprehensive income | 184 | |||
| Comprehensive loss: | (840) | (3,057) | (14,959) | |
| Comprehensive income (loss), net of tax, attributable to noncontrolling interest | (12) | 296 | 184 | |
| Other undisclosed comprehensive loss, net of tax, attributable to parent | (305) | |||
| Comprehensive loss, net of tax, attributable to parent: | (852) | (2,761) | (15,080) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.